Skip to main content

Peer Review reports

From: Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Original Submission
10 Oct 2023 Submitted Original manuscript
5 Dec 2023 Reviewed Reviewer Report
7 Dec 2023 Reviewed Reviewer Report
3 Jan 2024 Author responded Author comments - Yanfei Liu
Resubmission - Version 2
3 Jan 2024 Submitted Manuscript version 2
5 Jan 2024 Reviewed Reviewer Report
16 Jan 2024 Reviewed Reviewer Report
25 Jan 2024 Author responded Author comments - Yanfei Liu
Resubmission - Version 3
25 Jan 2024 Submitted Manuscript version 3
31 Jan 2024 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
28 Feb 2024 Editorially accepted
7 Mar 2024 Article published 10.1186/s12916-024-03329-8

You can find further information about peer review here.

Back to article page